+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to compare the safety and effectiveness of two types of multifocal contact lenses, ACUVUE4 OASYS MAX 1-Day Multifocal and DAILIES4 AquaComfort Plus4 Multifocal. The study is designed as a randomized, single-masked clinical trial with two parallel groups to evaluate visual acuity and ocular safety in adults aged 40 to 70 years. Participants will be monitored for both near and distance vision performance as well as any lens-related eye events. Participants will be randomly assigned to wear either the Senofilcon A lens ACUVUE4 OASYS MAX 1-Day Multifocal or the Nelfilcon A lens DAILIES4 AquaComfort Plus4 Multifocal for the duration of the study. The study consists of four visits where the lenses performance is assessed at one week and one month after initial fitting. Both lenses are soft multifocal contact lenses designed to correct presbyopia and improve visual acuity at various distances. During the study, participants will undergo evaluations of binocular visual acuity at distance, intermediate, and near ranges, along with monitoring for ocular adverse events and slit lamp findings. The primary outcomes measured include visual acuity at one week and the incidence of lens-related eye issues up to one month. This study requires participants to attend four visits over the course of the study period, which lasts approximately one month after lens fitting.

Age: 40Years - 70YearsAll GendersPhase Not Applicable
11 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a novel spectacle lens to control myopia progression in young children aged 6 to 8 years. This randomized, controlled, double-masked study aims to validate results from previous trials by comparing the new spectacle lens with a standard single vision, impact-resistant lens. The 12-month results will help predict the treatments effectiveness over three years. Participants are randomly assigned to one of two groups one group will wear the new experimental spectacle lenses, and the other will wear standard single vision lenses. Both types of lenses are impact-resistant. The study requires children to wear their assigned spectacles for at least 10 hours daily, except during sleep, swimming, or other activities where wearing glasses is unsafe or impractical. Children will be involved in the study for 24 months, during which their vision will be regularly checked through tests including spherical equivalent refraction, axial length measurement, and visual acuity assessments. The study monitors how well the lenses control myopia progression and ensures safety by tracking any ocular or systemic conditions. Parent or guardian consent is required for participation.

Age: 6Years - 8YearsAll GendersPhase Not Applicable
14 locations
R

Actively Recruiting

Researchers are evaluating the effects of intra-articular injections of Allocetra in people aged 64 and older who have moderate-to-severe primary knee osteoarthritis, a condition where joint cartilage breaks down and causes chronic knee inflammation, pain, and functional issues. This randomized, double-blind, placebo-controlled Phase IIb study compares Allocetra to a placebo to assess its potential benefits. Participants will receive three ultrasound-guided injections directly into the affected knee on Days 0, 14, and 28. Allocetra is a cell-based therapy made from modified allogeneic peripheral blood mononuclear cells designed to influence immune cells in the knee joint. The study includes two groups one receiving Allocetra injections and the other receiving placebo injections. After treatment, participants will be followed for 12 months to monitor outcomes. Throughout the study, participants will undergo assessments including pain and function evaluations using the Western Ontario and McMaster Universities Arthritis Index WOMAC at 3 and 6 months, safety monitoring for six months, and quality of life measurements. Researchers will track daily pain scores and other functional scales to evaluate the treatments impact. The studys total duration from treatment to follow-up is about one year.

Age: 64Years +All GendersPhase 2
17 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations